Patterns and Clinical Impact of Alectinib Dose Reduction in Patients with ALK-Positive Non- Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
To, B. [1 ]
Farid, S. [1 ]
Zhao, S. [1 ]
Li, M. [1 ]
Amirmokhtari, N. [1 ]
Wei, L. [1 ]
Memmott, R. [1 ]
Alahmadi, A. [1 ]
He, K. [1 ]
Kaufman, J. [1 ]
Roof, L. [1 ]
Shields, P. [1 ]
Carbone, D. [1 ]
Otterson, G. [1 ]
Presley, C. [1 ]
Owen, D. [1 ]
机构：
[1] Ohio State Univ, Med Ctr, Columbus, OH USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
alectinib; dose reduction; CNS disease;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12B.10
引用
收藏
页码：S644 / S645
页数：2
相关论文
共 50 条
  • [21] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2019, 36 : 1114 - 1125
  • [22] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2019, 36 (05) : 1114 - 1125
  • [23] Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer
    Chai, Q.
    Gu, C.
    Zhang, Y. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S738 - S738
  • [24] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [25] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Camidge, D. R.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [26] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [27] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients
    Yoshida, T.
    Oya, Y.
    Tanaka, K.
    Junichi, S.
    Yoshitsugu, H.
    Hida, T.
    Yatabe, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S619 - S619
  • [28] Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules
    Ishiura, Yoshihisa
    Nomura, Shosaku
    Ishii, Yuka
    Imai, Kai
    Nakahama, Kahori
    Sawai, Yusuke
    Tamaki, Takeshi
    Shimizu, Toshiki
    Miyashita, Naoyuki
    Ito, Tomoki
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (05) : 1283 - 1285
  • [29] Alectinib/crizotinibDevelopment of drug resistance in ALK-positive non-small cell lung cancer: case report
    Reactions Weekly, 2020, 1829 (1) : 23 - 23
  • [30] Bayesian analysis supports the role of alectinib and ensartinib for ALK-positive non-small cell lung cancer
    Rizzo, Alessandro
    THORACIC CANCER, 2023, 14 (13) : 1217 - 1217
12345